Meet PSI at EANM Congress 2026!
PSI CRO is attending EANM Congress 2026 to discuss how sponsors can maintain predictable delivery and operational control in pivotal radiopharmaceutical and theranostic clinical trials.
Radiopharmaceutical development programs continue to place unique pressure on site readiness, imaging workflows, isotope logistics, and participant coordination across global regions. PSI has supported 40% of all industry pivotal radiopharmaceutical and radioligand therapy (RLT) trials, with operational expertise spanning imaging-intensive protocols, global site activation, and specialized site support through its Specialized Study Support Services model.
Visit PSI at Booth #254
Meet with the PSI team to discuss operational strategies for radiopharmaceutical and theranostic trials, including accelerating startup timelines, strengthening site performance, and scaling phase 2–3 radiopharmaceutical programs across North America, Europe, and Asia-Pacific.
Attending team members:
- Michael Sommer
Senior Director, Business Development - Lucy Knight
Director, Project Management
Related resources:
Blog: Radiopharmaceutical advances expose the need for specialized trial support
Case Study: FDA approval of a first of its kind theranostic in under 4 years with PSI’s help
Webinar: From Early Promise to Pivotal Success: Operationalizing RLT Trials for Scale [Orano Med + PSI]
White Paper: The operational reality of agentic AI in phase 2-3 trials
